All News

    Personalized Kidney Cancer Vaccine May Help Prevent Future Relapse

    February 11th 2025, 4:00pm

    Video

    In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

    FDA Approval of Calquence Combo Brings Optimism in MCL

    February 11th 2025, 2:00pm

    Article

    Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.

    The Importance of Utilizing Support Networks Following a Cancer Diagnosis

    February 10th 2025, 10:00pm

    Video

    Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.

    Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care

    February 10th 2025, 8:00pm

    Article

    The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.

    The Effects of Scanxiety on ‘Normal’ Life

    February 10th 2025, 6:00pm

    Article

    As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and oncology appointment.

    An Expert Breaks Down What DPD Is and Labeling Updates From The FDA

    February 10th 2025, 5:00pm

    Video

    Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

    THIO and Libtayo Extends OS in NSCLC Following Progression on SOC Therapy

    February 10th 2025, 4:00pm

    Article

    THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

    Lonsurf Shows Survival Benefit Over Placebo in Stage 4 Colorectal Cancer

    February 10th 2025, 2:00pm

    Article

    In patients with residual disease after curative resection of colorectal cancer, Lonsurf showed a numerical improvement in DFS, though not significant.

    Pelareorep With Chemo and Tecentriq Shows Acceptable Safety in Metastatic PDAC

    February 9th 2025, 7:00pm

    Article

    Pelareorep plus chemotherapy with or without Tecentriq had an acceptable safety profile in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma.

    From Patient 3737 to Advocate: The Life-Changing Power of Clinical Trials

    February 9th 2025, 3:00pm

    Article

    Melinda Bachini is the Chief Patient Officer at the Cholangiocarcinoma Foundation and a 15-year survivor of cholangiocarcinoma.